NOTICE OF MAILING CHANGE
☐ Check here if you wish to discontinue receiving this publication
☐ Check here if your address has changed and you wish to continue receiving this publication. Make corrections below and mail this page to:

NIH Guide
Distribution Center
National Institutes of Health
Room B4B-N-08, Building 31
Bethesda, Maryland 20892

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
OFFICIAL BUSINESS
Penalty for Private Use, $500

The NIH Guide announces scientific initiatives and provides policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in extramural programs administered by the National Institutes of Health.

Vol. 17, No. 14
April 15, 1988
NOTICES

CHANGED RECEIPT DATES FOR REVISED APPLICATIONS ........................................ 1
Division of Research Grants
Index: DIVISION OF RESEARCH GRANTS

DATED ANNOUNCEMENTS (RFPs AND RFAs)

NEUROPSYCHOLOGICAL TESTING FOR CHILDREN AND ADULTS WITH HIV INFECTION (RFP)
National Cancer Institute ................................................................. 1
Index: CANCER

ANALYSIS OF LARGE DATA BASES FOR RISKS/BENEFITS OF CONTRACEPTION
AND HORMONE USE (RFP) ............................................................... 2
National Institute of Child Health and Human Development
Index: CHILD HEALTH AND HUMAN DEVELOPMENT

RESEARCH AND DEMONSTRATION OF INNOVATIVE NURSING CARE DELIVERY MODELS (RFA)... 2
National Center for Nursing Research
Health Resources and Service Administration
Index: NATIONAL CENTER FOR NURSING RESEARCH
HEALTH RESOURCES AND SERVICE ADMINISTRATION

COOPERATIVE AGREEMENTS FOR NATIONAL COOPERATIVE DRUG DISCOVERY GROUPS (RFA)
National Cancer Institute ............................................................... 4
Index: CANCER

ERRATUM

AVAILABILITY OF DATABASE AND SERUM COLLECTION OF THE CHILD HEALTH AND
DEVELOPMENT STUDIES ................................................................. 6
National Institute of Child Health and Human Development
Index: CHILD HEALTH AND HUMAN DEVELOPMENT
NOTICES

CHANGED RECEIPT DATES FOR REVISED APPLICATIONS

P.T. 34; K.W. 1014002, 0710030

Division of Research Grants

There has been a change in the receipt dates for revised research grant and Research Career Development Award applications. Effective with the next receipt dates (June/July 1988), all revised applications for both new and competing continuation grants will be due on March 1, July 1, and November 1. This notice does not apply to revised program project and center grant applications which will continue to be due on February 1, June 1, and October 1, nor does it apply to revised National Research Service Award applications which will continue to be due on January 10, May 10, and September 10. The new overall receipt, review, and award schedule is summarized in the following chart.

<table>
<thead>
<tr>
<th>Application Receipt Dates</th>
<th>Initial Review</th>
<th>National Advisory Council or Board Dates</th>
<th>Earliest Possible Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Unless specified differently in additional instructions, a program announcement, or a request for applications)</td>
<td>Dates</td>
<td>Dates</td>
<td>Dates</td>
</tr>
<tr>
<td>May 10</td>
<td>June 1</td>
<td>July 1</td>
<td>Oct.-Nov.</td>
</tr>
<tr>
<td>Sept 10</td>
<td>Oct. 1</td>
<td>Nov. 1</td>
<td>Feb.-Mar.</td>
</tr>
</tbody>
</table>

For ALL* All NEW RCDA & COMPETING
Research National research grant CONTINUATION, applications SUPPLEMENTAL, Service ALL* Program and REVISED
Award Project and research grant application Center grant and RCDA applications

RCDA = Research Career Development Award
* Includes NEW, COMPETING CONTINUATION, SUPPLEMENTAL, and REVISED

Note: Unsolicited AIDS applications submitted for expedited review will continue to be received on January 2, May 1 and September 1, including revised applications (See NIH Guide for Grants and Contracts, Vol. 17, No. 9, March 11, 1988, page 1).

DATED ANNOUNCEMENTS (RFPs AND RFAs)

NEUROPSYCHOLOGICAL TESTING FOR CHILDREN AND ADULTS WITH HIV INFECTION

RFP AVAILABLE: NCI-CM-87263-19

P.T. 34; K.W. 1002030, 0414000, 0414004

National Cancer Institute

The National Cancer Institute (NCI) seeks a contractor to perform neuropsychological testing for children and adults with Human Immunodeficiency Virus (HIV) infection. This will be accomplished through the use of neuropsychological evaluation, personality assessment, and structured standardized clinical interviews and observations. It is anticipated that each year for 3 years there will be a total of 50 pediatric and 50 adult HIV patients to be evaluated. A total patient population of 300 patients is the goal. Each patient will be evaluated three times a year: a complete evaluation at the beginning and a partial testing sequence for the second and fourth quarter evaluations. The contractor shall provide comprehensive, state-of-the-art neuropsychological and neuropsychiatric evaluations of pediatric and adult NCI patients with HIV infection. The nature of the acquisition requirements mandates that the contractor have (or provide evidence they can establish prior to contract award) the ability to provide within 24 hours the personnel and material to accomplish the prescribed work. The contractor must perform most of the required assessments and other work at the Clinical Center, National Institutes of Health (NIH), Bethesda, Maryland. In addition, the contractor must be able to show the availability for "overflow" testing and assessment space which is conveniently located with respect to the Clinical Center, NIH. Requests for the solicitation document
should reference the RFP number and be forwarded to the address below. The RFP will be available on 4/25/88 and responses will be due on 5/25/88.

Copies of the RFP may be obtained by sending a written request to:

Zetherine Gore
Contract Specialist
Treatment Contracts Section, Research Contracts Branch
National Cancer Institute
Blair Building, Room 228
Bethesda, Maryland 20892
Telephone: (301) 427-8737

ANALYSIS OF LARGE DATA BASES FOR RISKS/BENEFITS OF CONTRACEPTION AND HORMONE USE

RFP AVAILABLE: NICHD-CE-88-8
P.T. 34; K.W. 0750020, 0411005, 0760025

National Institute of Child Health and Human Development

THIS PROCUREMENT IS TOTALLY SET-ASIDE FOR SMALL BUSINESS CONCERNS. FOR PURPOSES OF THIS PROCUREMENT, A SMALL BUSINESS CONCERN IS A CONCERN, INCLUDING ITS AFFILIATES, WHICH IS INDEPENDENTLY OWNED AND OPERATED, IS NOT DOMINANT IN THE FIELD OF OPERATION IN WHICH IT IS PROPOSING ON GOVERNMENT CONTRACTS, AND WHOSE AVERAGE ANNUAL RECEIPTS FOR THE PRECEDING THREE FISCAL YEARS DO NOT EXCEED $3.5 MILLION.

The Contraceptive Evaluation Branch, Center for Population Research, National Institute of Child Health and Human Development, National Institutes of Health, is seeking small business organizations capable of analyzing large resource data bases to characterize the benefits, risks, safety and use patterns of contraception. Analyses will include examination of general hypotheses that certain contraceptive choices will alter overall risk and risk of mortality. Hypotheses concerning putative relationships between particular contraceptives and specific disease entities will be tested.

Organizations responding to this announcement should have extensive experience in reproductive epidemiology and demonstrated knowledge of the statistical methods necessary to model the hypothesized relationships arising from prospective, retrospective, and cross-sectional studies. In addition, the offeror should have the capability to interpret these analyses and generate new hypotheses. It is estimated that a single contract award will be made for a two-year performance period.

This announcement is not a request for proposals (RFP). RFP-NICHD-CE-88-8 will be issued on or about April 18, 1988. Responses from small business organizations that believe they can meet the requirements of this project will be due 60 days thereafter. Copies of the RFP may be obtained by sending a written request to the address listed below. Please enclose a self-addressed label.

Paul J. Duska, Contracting Officer
Contracts Management Section, OGC
National Institute of Child Health and Human Development
Executive Plaza North, Room 610
Bethesda, Maryland 20892

RESEARCH AND DEMONSTRATION OF INNOVATIVE NURSING CARE DELIVERY MODELS

RFA Available: 88-NR-01
P.T. 34; K.W. 0785130, 0730050

National Center for Nursing Research
Health Resources and Service Administration

Application Receipt Date: July 11, 1988
Letter of Intent Receipt Date: May 9, 1988

BACKGROUND

Examination of the current apparent nursing shortage has yielded evidence that multiple factors interact in the health care system which influence the number
and quality of nursing resources available in hospitals. Hospitals, the largest employer of nurses, influence both nurses' and the public's perception of nursing care delivery by the methods they use to facilitate professional nursing practice and the methods they use to stimulate recruitment and retention of nursing personnel.

The research capability in related areas is now sufficiently developed to permit a systematic study of hospitals in which well-designed demonstration projects can be implemented. Such research and demonstration activities will be useful in stimulating improvement of quality of patient care delivery and in demonstrating how the shortage of nursing personnel in hospitals can be resolved.

RESEARCH GOALS AND SCOPE

This cooperative agreement has been designed to develop, implement and study replicable innovative nursing care delivery models for hospitals. These models are designed to increase available nursing resources, examine factors which influence quality of patient care and patient outcomes and to take into consideration the goals and benefits of the models in the three study hospitals in each project.

ELIGIBILITY AND REVIEW

The National Center for Nursing Research, NIH, and the Division of Nursing, BHPR, HRSA, invite cooperative agreement applications for research and demonstration projects from non-profit organizations and institutions that have demonstrated expertise in advances in nursing practice, research and education; that have demonstrated ability to conduct hospital-based clinical research projects involving faculty from schools of nursing and hospital-based clinical nurse researchers; and that have demonstrated capability in developing and managing multi-site research and demonstration projects. Eligibility is restricted to U.S. institutions.

Applications will be received by the Division of Research Grants. Applicants must use PHS Form 398 (Revised September 1986) Application for Public Health Service Center. A receipt date of July 11, 1988 has been established.

Applications received after this date will not be accepted for review in this competition. The RFA label provided with the instructions must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of your application such that it may not reach the review committee in time for review. All applications submitted in response to this RFA will be reviewed for scientific merit by a special peer review group constituted by the National Center for Nursing Research and the Division of Nursing for program considerations. Additionally, the National Advisory Council on Nurse Training and the National Center for Nursing Research Advisory Council will provide program review and recommendation.

MECHANISM OF SUPPORT

Awards via cooperative agreement will support funded projects. A total of up to $400,000 of Federal funds will be allocated to support the initial year's awards. The start date for funded projects will be approximately September 8, 1988. It is anticipated that one or two awards will be made with the possibility that additional awards may be made in subsequent fiscal years. The number of awards and the specific amounts of awards will depend on the merit and scope of the applications received and the availability of funds.

All policies and requirements of DHHS, PHS and NIH which govern the cooperative agreement awards will apply.

INQUIRIES

A copy of the complete RFA, which describes the research goals and scope, terms and conditions, review procedures and criteria, and method of applying, may be obtained by contacting:

Dr. Patricia Moritz
Chief, Nursing Systems Branch
National Center for Nursing Research, NIH
Building 38A, Room B2E17
Bethesda, Maryland 20894
Telephone: (301) 496-0523

or
COOPERATIVE AGREEMENTS FOR NATIONAL COOPERATIVE DRUG DISCOVERY GROUPS

RENEWAL RFA AVAILABLE: NIH-NCI-DCT-DTP-83-6
84-CA-22
87-CA-01
87-CA-02
87-CA-24
87-CA-25
87-CA-26

P.T. 34; K.W. 0715035, 0755035, 0755020, 0740020

National Cancer Institute
Application Receipt Date: June 8, 1988

INTRODUCTION

The purpose of this announcement is to invite current awardees of the National Cooperative Drug Discovery Group (NCDDG) Program to submit renewal applications.

ELIGIBILITY

Any Principal Investigator with an active U01 award made under one of the following Requests for Applications (RFAs) is eligible to submit a competing continuation application: NIH-NCI-DCT-DTP-83-6 (Vol. 12, No. 7, July 15, 1983); 84-CA-22 (Vol. 13, No. 9, August 3, 1984); 87-CA-01 and 87-CA-02 (Vol. 15, No. 20, October 3, 1986); 87-CA-24, 87-CA-25, and 87-CA-26 (Vol. 16, No. 29, August 28, 1987).

RESEARCH GOALS AND SCOPE

The National Cancer Institute (NCI) initiated the NCDDG Program in 1983, to exploit exciting developments in biomedical research into new and more effective treatments for cancer. Multidisciplinary and usually multi-institutional teams of talented scientists from academic, non-profit research and commercial organizations are brought together to conceive, create, evaluate and develop new drugs, models or treatment strategies. Scientific approaches are broad and limited only by the creativity and ability of the Groups. Active participation by industry is encouraged to allow this segment of the scientific community to contribute its considerable intellectual and material resources. NCI serves as a partner to facilitate and expedite the translation of findings from the laboratory to the clinic.

This program is described in the Catalog of Federal Domestic Assistance No. 13.395. Cancer Treatment Research. Awards will be made under the authority of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.

RFAs issued in 1983 (NIH-NCI-DCT-DTP-83-6) and 1984 (84-CA-22) were designed to exploit general mechanistic differences between normal and cancer cells. RFAs were issued in 1986 to exploit unique features of lung cancer (87-CA-01) and colon cancer (87-CA-02). In 1987, three additional RFAs were issued. RFA 87-CA-24 focused on a disease-oriented approach for the discovery of new anticancer treatments with the cancer type left to the discretion of the applicant. RFA 87-CA-25 was a re-issuance of the original mechanism of action based approach to the discovery of new therapies, and RFA 87-CA-26 represented an extension of the program to stimulate the discovery of novel models which will more accurately predict the clinical efficacy of new anticancer drugs and treatment strategies.

APPLICATION PROCEDURES

Awards will be made as cooperative agreements. Assistance via cooperative agreement differs from that of all other types of research grants in that the
The cooperative agreement funding mechanism anticipates substantial NCI staff participation during performance. However, the applying Group must define its objectives in accord with its own interests and perceptions of approaches to the discovery of new therapies, models or treatment strategies. The role of NCI as a member of the Group is described in the original RFA. Essentially, the extramural NCI program staff concerned with the administration of grants and contracts will apply its experience and appropriate resources to facilitate and stimulate the realization of Group objectives.

The Principal Investigator's (PI's) institution will be responsible for the Group's application. Awards will be made to the applicant institution on behalf of the Group as a whole and not to individual Laboratory Programs within the Group. The PI's institution will provide a Central Operations Office for the Group, and will be responsible for the performance of the entire Group and will be accountable for the funds awarded.

NCI plans to make awards for project periods up to five years. Awards will be made only to scientifically meritorious applications and no funds have been set aside for the initial year's funding. The application receipt date will be June 8, and the earliest possible starting date will be April 1 of the following year. Further competing continuation applications will be by specific invitation of NCI.

Because of the complexity of NCDDG applications, the PI should contact the Program Director at least six months before the final year of the grant to discuss renewal procedures. A letter of intent should be submitted at least four months in advance of the application receipt date to Dr. J.A.R. Mead, Program Director, at the address listed below. The letter of intent should refer to the original RFA by number and should include the title of the application, the name and affiliation of the PI, the titles of the individual projects, and the names and affiliations of the proposed project leaders.

Mail the letter of intent to:

J.A.R. Mead, Ph.D.
Program Director
Grants and Contracts Operations Branch
Developmental Therapeutics Program
Division of Cancer Treatment
National Cancer Institute
Executive Plaza North, Room 832
Bethesda, Maryland 20892
Telephone: (301) 496-8783

The standard research Grant Application Form PHS 398 (Rev. 9/86) should be used for the application. For purposes of identification and processing, check the box marked "YES", identify the number of this program announcement, and type the phrase "National Cooperative Drug Discovery Group" in item 2 on the face page of the application. In the Introduction Section, reference should be made to the original RFA number. In addition to the usual sections on progress and future studies, it should be noted that the applicant must describe NCI Program involvement in the cooperative agreement.

Mail a signed, typewritten original of the application, including a single Checklist, and four signed, exact single-sided photocopies in one package to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, Maryland 20892

To expedite the review process, submit two additional copies of your application directly to:

Mr. Hernon Fox
Referral Officer
Westwood Building, Room 848
National Cancer Institute
Bethesda, Maryland 20892
Telephone: (301) 496-3428

REVIEW PROCEDURES AND CRITERIA

Support for this program will be through the cooperative agreement mechanism. All PHS and NIH grants policies will apply to applications received in response to this announcement. Applications will be reviewed by NCI staff to determine administrative and programmatic responsiveness to the original RFA. Those judged to be nonresponsive will be administratively withdrawn.
Responsive applications will be peer-reviewed for scientific and technical merit by a Special Review Committee convened by the Division of Extramural Activities, NCI. Review criteria will be the same as those in the original RFA. The second level of review for relevance to the National Cancer Program will be made by the National Cancer Advisory Board.

INQUIRIES

Additional information and a copy of the original RFA may be obtained from:

George S. Johnson, Ph.D.
or Mary K. Wolpert, Ph.D.
Executive Plaza North, Room 830
Grants and Contracts Operations Branch
Developmental Therapeutics Program
Division of Cancer Treatment
National Cancer Institute
Bethesda, Maryland 20892
Telephone: (301) 496-8783

ERRATUM

AVAILABILITY OF DATABASE AND SERUM COLLECTION OF THE CHILD HEALTH AND DEVELOPMENT STUDIES

P.T. 36; K.W. 0780005, 1004008
National Institute of Child Health and Human Development

The National Institute of Child Health and Human Development (NICHD) announced the availability of the database and serum collection of the Child Health and Development Studies (CHDS) in the NIH Guide for Grants and Contracts, February 19, 1988, Volume 17, Number 6. Copies of the database can be obtained on magnetic tape with a User's Guide at cost from the National Technical Information Service (NTIS), 5285 Port Royal Road, Springfield, Virginia 22161, of the U.S. Department of Commerce. The telephone number for sales is (703) 487-4650, and the current cost is $400. In the second paragraph of the program announcement, the NTIS accession number was erroneously reported. The correct NTIS accession is B88-146188. Additional information may be obtained by calling the NTIS Computer Products Office at (703) 487-4763. Access to the serum collection, stored at -20 C at the Frederick Cancer Research Facility (FCRF), can be gained through the custodian of the serum collection, Gilman D. Grave, M.D., Chief, Endocrinology, Nutrition, and Growth Branch, Center for Research for Mothers and Children, NICHD.

The main objectives of the CHDS were to relate biologic, genetic, medical, and environmental factors in the parents to the normal and abnormal development of their offspring. Special emphasis was placed on the relationships of events during pregnancy, labor, and delivery to fetal death, perinatal mortality, congenital defects, infant morbidity/mortality, and growth and development during infancy and childhood.

A longitudinal study design was used to generate data on mothers, fathers, and their offspring. Data were gathered on 20,754 pregnancies and their outcomes from four sources: (1) Pregnancy interviews; (2) Medical records of pregnancy, labor, and delivery; (3) Medical records of the offspring; and (4) Developmental examinations of subcohorts of the children at ages 5, 9-11, and 15-17. The cohort of pregnant women and their 18,751 children who survived the neonatal period (including 66 pairs of monozygotic and 115 pairs of dizygotic twins) is broadly representative from ethnic and socioeconomic viewpoints. Serum samples were drawn during each trimester of pregnancy and postpartum. An average of three serum samples per pregnancy was obtained from 18,400 pregnancies. Serum samples were also collected from approximately 12,000 husbands. Cord blood was also collected and approximately 3,000 samples are stored in the serum collection.

**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS THE CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH. APPLICANTS WHO USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S REQUIREMENTS FOR SHOWING A STREET ADDRESS. THE ADDRESS FOR THE WESTWOOD BUILDING IS:**

5333 Westbard Avenue
Bethesda, Maryland 20816